HYHyoung-Mo Yang

Hyoung-Mo Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hyoung-Mo Yang has a total of 332 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients

    by Yangyoun Lee, Hong‐Seok Lim, Kyoung‐Woo Seo, Hyoung‐Mo Yang, So‐Yeon Choi, Seung‐Jea Tahk, Myeong‐Ho Yoon

    Background: Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims: We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and DP‐DES in patients undergoing routine percutaneous coronary intervention (PCI). Methods: We analyzed consecutive patients undergoing PCI with second‐generation or newer DES at a single institution (2010–2021). Propensity scores were estimated using prespecified clinical, angiographic, and procedural covariates, and 1:1 nearest‐neighbor matching was performed. The primary endpoint was 5‐year target lesion failure (TLF: cardiac death, target vessel myocardial infarction [TV‐MI], or clinically driven target lesion revascularization [TLR]). Key secondary endpoints were 1‐year TLF, all‐cause mortality, and ARC‐2 definite or probable stent thrombosis. A prespecified 1‐year landmark analysis evaluated outcomes from 0 to 1 and 1 to 5 years. Results: After matching, 2197 pairs (4394 patients) were included. At 5 years, TLF occurred in 7.9% of BP‐DES and 7.9% of DP‐DES patients (HR 1.01, 95% CI 0.81–1.26; p = 0.936). No statistically significant differences were observed in secondary endpoints, including 1‐year TLF, individual TLF components, all‐cause mortality, or ARC‐2 definite or probable stent thrombosis. All‐cause mortality at 5 years was similar between groups (7.1% vs. 8.2%; HR 0.87, 95% CI 0.69–1.09; p = 0.213); however, in the 1–5‐year landmark period, mortality was numerically lower with BP‐DES (HR 0.73, 95% CI 0.53–1.00; nominal p = 0.047). No significant treatment‐by‐subgroup interactions were observed. Conclusions: In routine PCI using second‐generation or newer DES, BP‐DES and DP‐DES demonstrated comparable 5‐year TLF. The potential late survival signal with BP‐DES is hypothesis‐generating and should be interpreted cautiously given the observational design.


  • Open Access

    Artificial intelligence-enhanced electrocardiography for acute myocardial infarction detection: a systematic review

    by Yangyoun Lee, Jung Hwan Ahn, Hyoung-Mo Yang

    Background: Artificial intelligence (AI) shows promise for improving electrocardiogram (ECG)-based acute myocardial infarction (AMI) detection, but clinical readiness remains uncertain. We aimed to conduct a systematic synthesis informed by a structured search of AI-enhanced ECG systems to evaluate their performance, validation quality, and implementation readiness. Methods: We conducted a structured search of PubMed and Embase (publication date limits: January 1, 2017, to August 31, 2025; last searched: February 18, 2026) for English-language human studies that developed or validated AI models for ECG-based AMI diagnosis, extracting data on architectures, clinical applications, validation approaches, and performance metrics; we excluded non-original publications and studies that were non-English or non-human studies or did not use ECG input or did not address AMI diagnosis. Results: We included 88 studies; the total number of participants was not estimable because sample sizes were inconsistently reported across studies. Among 88 identified studies, convolutional neural networks predominated (51/88, 58%). Most studies were retrospective (80/88, 91%) and used 12-lead ECG (64/88, 73%). Reported performance varied widely [area under the receiver operating characteristic curve (AUROC), 0.700–0.999; sensitivity, 67.7–100.0%; specificity, 73.3–100.0%], with promising results for detecting subtle ischemic patterns in non-ST-elevation and occlusion myocardial infarction (OMI). However, only 33/88 (37.5%) performed external validation. Public datasets were used in 50/88 (57%) and institutional patient cohorts in 43/88 (49%); several studies used both sources. More complex architectures did not consistently demonstrate superior accuracy, though heterogeneity in study designs limits definitive conclusions. Conclusions: AI demonstrates substantial technical potential for AMI detection, particularly for subtle ischemic patterns. However, critical gaps impede clinical deployment: insufficient external validation, reliance on curated datasets with limited generalizability, absence of standardized evaluation frameworks, and insufficient evidence on patient-centered outcomes. Future research must prioritize prospective multicenter validation, standardized benchmarks with rigorous reference standards, and real-world implementation studies examining clinical outcomes and workflow integration. Technical feasibility is established; clinical impact now depends on validation rigor and pragmatic deployment.


  • Open Access

    Ultrathin Bioresorbable Polymer Sirolimus-Eluting Orsiro Stents for Complex Percutaneous Coronary Intervention

    by Ho Sung Jeon, Su Yong Kim, Jung-Hee Lee, Jun-Won Lee, Young Jin Youn, Hyoung-Mo Yang, Seong-Ill Woo, Sang-Yong Yoo, Jooho Lee, Sang Hoon Shin, et al.

    Jeon HS, et al. J Cardiovasc Interv. 2025 Jan;4:e11. https://doi.org/10.54912/jci.2024.0034


  • Open Access

    Osfit™, a Novel Stent Designed for the Treatment of Coronary Ostial Lesions: Initial Clinical Experience and Intravascular Ultrasound Evaluation

    by Kyoung-Woo Seo, Seung-Jea Tahk, Hyoung-Mo Yang, Hong-Seok Lim, Myeong-Ho Yoon, So-Yeon Choi

    Seo KW, et al. Korean Circ J. 2025 Feb;55:e30. https://doi.org/10.4070/kcj.2024.0256


  • Real-World Effectiveness of Statin Therapy in Adult Asthma

    by ChulHyoung Park, Jae-Hyuk Jang, Chungsoo Kim, Youngsoo Lee, Eunyoung Lee, Hyoung-Mo Yang, Rae Woong Park, Hae-Sim Park


  • Open Access

    Epicardial Adipose Tissue Thickness Is Related to Plaque Composition in Coronary Artery Disease

    by Soon Sang Park, Jisung Jung, Gary S. Mintz, Uram Jin, Jin-Sun Park, Bumhee Park, Han-Bit Shin, Kyoung-Woo Seo, Hyoung-Mo Yang, Hong-Seok Lim, et al.

    (1) Background: Currently, limited data are available regarding the relationship between epicardial fat and plaque composition. The aim of this study was to assess the relationship between visceral fat surrounding the heart and the lipid core burden in patients with coronary artery diseases; (2) Methods: Overall, 331 patients undergoing coronary angiography with combined near-infrared spectroscopy and intravascular ultrasound imaging were evaluated for epicardial adipose tissue (EAT) thickness using transthoracic echocardiography. Patients were divided into thick EAT and thin EAT groups according to the median value; (3) Results: There was a positive correlation between EAT thickness and maxLCBI4mm, and maxLCBI4mm was significantly higher in the thick EAT group compared to the thin EAT group (437 vs. 293, p < 0.001). EAT thickness was an independent predictor of maxLCBI4mm ≥ 400 along with age, low-density lipoprotein-cholesterol level, acute coronary syndrome presentation, and plaque burden in a multiple linear regression model. Receiver operating characteristic curve analysis showed that EAT thickness was a predictor for maxLCBI4mm ≥ 400; (4) Conclusions: In the present study, EAT thickness is related to the lipid core burden assessed by NIRS-IVUS in patients with CAD which suggests that EAT may affect the stability of the plaques in coronary arteries.


  • Efficacy and Safety of 3 Versus 6 Months of Dual-Antiplatelet Therapy in Patients Implanted With Coroflex ISAR Stents: A Prospective, Multicenter, Randomized Clinical Trial

    by Uram Jin, Kyoung-Woo Seo, Hyoung-Mo Yang, Hong-Seok Lim, Byoung-Joo Choi, So-Yeon Choi, Joon-Han Shin, Seung-Jea Tahk, Sang-Yong Yoo, Seung Woon Rha, et al.

    This study examined the efficacy and safety of 3- versus 6-month DAPT in patients implanted with Coroflex ISAR polymer-free DESs. Original Contribution from Journal of Invasive Cardiology. Coronary artery disease Drug-eluting stents dual-antiplatelet therapy duration of therapy


  • Usefulness of the trans‐stent fractional flow reserve gradient for predicting clinical outcomes

    by Hyoung‐Mo Yang, Hong‐Seok Lim, Myeong‐Ho Yoon, Kyoung‐Woo Seo, Byoung‐Joo Choi, So‐Yeon Choi, Gyo‐Seung Hwang, Seung‐Jea Tahk

    Objectives: We evaluated the usefulness of a fractional flow reserve (FFR) gradient across the stent (ΔFFRstent) for long‐term clinical outcomes after percutaneous coronary intervention (PCI) with a drug‐eluting stent (DES).Background: The clinical meaning of a trans‐stent pressure gradient after DES implantation has not been estimated adequately.Methods: FFR pull‐back and intravascular ultrasound (IVUS) were performed after successful PCI in 135 left anterior descending artery lesions. ΔFFRstent was defined as the FFR gradient across the stent. The ΔFFRstent/length was defined as the ΔFFRstent value divided by the total stent length multiplied by 10. Major adverse cardiac events (MACEs) were the composite of all‐cause death, target vessel‐related myocardial infarction, and target lesion revascularization.Results: Despite successful PCI, ΔFFRstent > 0 was observed in 98.5% of cases. ΔFFRstent ≥ 0.04 and ΔFFRstent/length ≥ 0.009 predicted suboptimal stenting defined as final minimal stent area < 5.5 mm2. During 2,183 ± 898 days, the MACE‐free survival rate was significantly lower in patients with ΔFFRstent ≥ 0.04 and ΔFFRstent/length ≥ 0.009 compared to those with lower values (69.6 vs. 93.4%, log‐rank p = .031; 72.1 vs. 97.7%, log‐rank p = .003, respectively). ΔFFRstent/length ≥ 0.009 (hazard ratio 10.1, p = .032) was an independent predictor of MACE.Conclusion: A trans‐stent FFR gradient was frequently observed. ΔFFRstent and ΔFFRstent/length are related to long‐term outcomes in DES‐treated patients.


  • Open Access

    Visit-to-visit systolic blood pressure variability in patients with ST-elevation myocardial infarction predicts long-term cardiovascular outcomes

    by Moon-Seung Soh, Jin-Sun Park, Kyoung-Woo Seo, Hyoung-Mo Yang, Hong-Seok Lim, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Seung-Jea Tahk, et al.

    Elevated visit-to-visit blood pressure variability (BPV), independent of mean BP, has been associated with cardiovascular events. However, its impact after ST-elevation myocardial infarction (STEMI) has not been established. This study aimed to investigate the prognostic impact of BPV on patients after STEMI. We analyzed the data and clinical outcomes of STEMI survivors who underwent successful primary coronary intervention from 2003 to 2009. BP was measured at discharge and at 1, 3, 6, 12, 24, and 36 months, and we calculated BPV as the intra-individual standard deviations (SDs) of systolic BP (SBP) across these measurements. We classified the patients as high and low-BPV group, and evaluated the outcomes: occurrence of major adverse cardiovascular events (MACEs), death, recurrent myocardial infarction, and target vessel revascularization within 60 months. We enrolled 343 patients, and mean follow-up duration was 68 ± 34 months (median: 76 months). Mean and median SBP SDs were 13.2 and 12.3 mmHg, and patients were divided into one of the two groups based on the median (high-BPV group = SD ≥ 12.3 mmHg; low-BPV group = SD < 12.3 mmHg). The MACE-free survival in the high-BPV group was significantly worse than that in low-BPV group (log-rank p = 0.035). For the high-BPV group, the risk of a MACE significantly increased by 57% (95% confidence interval: 1.03–2.39; p = 0.038). Visit-to-visit systolic BPV was associated with increased rates of adverse clinical outcomes in patients after STEMI. Careful assessment of BP and attempts to reduce BPV might be also important in STEMI survivors.


  • Open Access

    Lipid-Core Plaque Assessed by Near-Infrared Spectroscopy and Procedure Related Microvascular Injury

    by Hyoung-Mo Yang, Myeong-Ho Yoon, Hong-Seok Lim, Kyoung-Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Gyo-Seung Hwang, Seung-Jea Tahk

    Yang HM, et al. Korean Circ J. 2018 Aug;49:e100. https://doi.org/10.4070/kcj.2019.0072